Quell Therapeutics Ltd., a company that develops engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, entered into a collaboration, exclusive option, and license agreement with AstraZeneca to develop, manufacture and commercialize autologous, engineered Treg cell therapies for two autoimmune disease indications. Under the terms of the agreement, Quell’s toolbox of Treg cell engineering modules, including its Foxp3 Phenotype Lock, will be le...